<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715932</url>
  </required_header>
  <id_info>
    <org_study_id>MHICC-2020-003</org_study_id>
    <nct_id>NCT04715932</nct_id>
  </id_info>
  <brief_title>Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)</brief_title>
  <acronym>Hesperidin</acronym>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ingenew Pharmaceuticals Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to determine the effects of short-term treatment with&#xD;
      hesperidin on COVID-19 symptoms in comparison with a placebo. Treatment effects will be&#xD;
      observed through a symptoms diary that will be completed by participants throughout the study&#xD;
      and by taking the oral temperature daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled study. The study will include&#xD;
      subjects from Quebec diagnosed with COVID-19 infections. Following informed consent, 216&#xD;
      subjects meeting all inclusion and no exclusion criteria will be randomized to receive either&#xD;
      hesperidin 1000 mg once daily (q.d.)) or placebo (1:1 allocation ratio) for 14 days.&#xD;
      Investigational drug will be delivered to the patients' homes with an electronic oral&#xD;
      thermometer and a symptoms diary. Follow-up phone assessments will occur after 3, 7, 10, and&#xD;
      14 days following randomization for evaluation of COVID-19 symptoms. Electronic Case Report&#xD;
      Form (eCRF) will be completed by the research personnel over the phone with the patients. The&#xD;
      symptoms diary will be mailed back to the coordinating center at the end of the study in a&#xD;
      pre-addressed envelope.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Actual">June 7, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With COVID-19 Symptoms at Day 3.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With COVID-19 Symptoms at Day 7.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With COVID-19 Symptoms at Day 10.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With COVID-19 Symptoms at Day 14.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of COVID-19 Symptoms at Day 3.</measure>
    <time_frame>Day 3</time_frame>
    <description>Mean number of COVID-19 symptoms (range 0-13) at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of COVID-19 Symptoms at Day 7.</measure>
    <time_frame>Day 7</time_frame>
    <description>Mean number of COVID-19 symptoms (range 0-13) at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of COVID-19 Symptoms at Day 10.</measure>
    <time_frame>Day 10</time_frame>
    <description>Mean number of COVID-19 symptoms (range 0-13) at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of COVID-19 Symptoms at Day 14.</measure>
    <time_frame>Day 14</time_frame>
    <description>Mean number of COVID-19 symptoms (range 0-13) at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Complete Disappearance of Any Symptom.</measure>
    <time_frame>From randomization to occurence of first event, assessed up to 14 days</time_frame>
    <description>The descriptive statistics are the number of participants having complete disappearance of any symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Cough Symptom.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the cough symptom at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Cough Symptom.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the cough symptom at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Cough Symptom.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the cough symptom at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Cough Symptom.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the cough symptom at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Fever.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Fever.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Fever.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Fever.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Shortness of Breath.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of shortness of breath at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Shortness of Breath.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of shortness of breath at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Shortness of Breath.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of shortness of breath at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Shortness of Breath.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of shortness of breath at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Anosmia.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of anosmia at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Anosmia.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of anosmia at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Anosmia.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of anosmia at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Anosmia.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of anosmia at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Feverish or Chills.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of feverish or chills at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Feverish or Chills.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of feverish or chills at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Feverish or Chills.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of feverish or chills at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Feverish or Chills.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of feverish or chills at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Sore Throat.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of sore throat at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Sore Throat.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of sore throat at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Sore Throat.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of sore throat at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Sore Throat.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of sore throat at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Runny Nose.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of runny nose at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Runny Nose.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of runny nose at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Runny Nose.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of runny nose at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Runny Nose.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of runny nose at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Nausea/Vomiting.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of nausea/vomiting at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Nausea/Vomiting.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of nausea/vomiting at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Nausea/Vomiting.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of nausea/vomiting at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Nausea/Vomiting.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of nausea/vomiting at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Headache.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of headache at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Headache.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of headache at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Headache.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of headache at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Headache.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of headache at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of General Weakness.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of general weakness at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of General Weakness.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of general weakness at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of General Weakness.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of general weakness at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of General Weakness.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of general weakness at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Pain.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of pain at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Pain.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of pain at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Pain.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of pain at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Pain.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of pain at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Irritability/Confusion.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of irritability/confusion at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Irritability/Confusion.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of irritability/confusion at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Irritability/Confusion.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of irritability/confusion at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Irritability/Confusion.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of irritability/confusion at day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Diarrhea.</measure>
    <time_frame>Day 3</time_frame>
    <description>Number of subjects with the presence of diarrhea at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Diarrhea.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of subjects with the presence of diarrhea at day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Diarrhea.</measure>
    <time_frame>Day 10</time_frame>
    <description>Number of subjects with the presence of diarrhea at day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With the Presence of Diarrhea.</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of subjects with the presence of diarrhea at day 14.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Covid19</condition>
  <condition>Anosmia</condition>
  <condition>Fever</condition>
  <condition>Cough</condition>
  <condition>Shortness of Breath</condition>
  <condition>Sore Throat</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Headache</condition>
  <condition>Muscle Weakness</condition>
  <condition>Pain, Muscle</condition>
  <condition>Pain, Chest</condition>
  <condition>Pain, Joint</condition>
  <condition>Pain, Abdominal</condition>
  <condition>Pain</condition>
  <condition>Irritable Mood</condition>
  <condition>Confusion</condition>
  <arm_group>
    <arm_group_label>Hesperidin 1000mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1000mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hesperidin</intervention_name>
    <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
    <arm_group_label>Hesperidin 1000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
    <arm_group_label>Placebo 1000mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Covid-19 positive by polymerase chain reaction (PCR) testing;&#xD;
&#xD;
          -  Participant must be able to evaluate their symptoms and report them in the symptoms&#xD;
             diary;&#xD;
&#xD;
          -  Patients must be able to take their oral temperature daily with an electronic&#xD;
             thermometer provided to them with study materials;&#xD;
&#xD;
          -  Males and females, at least 18 years of age, capable and willing to provide informed&#xD;
             consent;&#xD;
&#xD;
          -  Female patient is either not of childbearing potential, defined as postmenopausal for&#xD;
             at least 1 year or surgically sterile, or is of childbearing potential and practicing&#xD;
             at least one method of contraception and preferably two complementary forms of&#xD;
             contraception including a barrier method (e.g. male or female condoms, spermicides,&#xD;
             sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study;&#xD;
&#xD;
          -  Patient must have received a diagnosis of COVID-19 infection within the last 48 hours&#xD;
             and have one or more symptoms;&#xD;
&#xD;
          -  Outpatient setting (not currently hospitalized or under immediate consideration for&#xD;
             hospitalization);&#xD;
&#xD;
          -  Patient must be able and willing to comply with the requirements of this study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient currently hospitalized or under immediate consideration for hospitalization;&#xD;
&#xD;
          -  Patient currently in shock or with hemodynamic instability;&#xD;
&#xD;
          -  Patient undergoing chemotherapy for cancer;&#xD;
&#xD;
          -  Patient is unable to take oral temperature using an electronic thermometer;&#xD;
&#xD;
          -  Patient who received at least one dose of the COVID-19 vaccine;&#xD;
&#xD;
          -  Female patient who is pregnant or breast-feeding or is considering becoming pregnant&#xD;
             during the study;&#xD;
&#xD;
          -  People taking anticoagulant/antiplatelet medications, those with bleeding disorders,&#xD;
             and people two weeks before or after surgery;&#xD;
&#xD;
          -  Patient is considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for the study;&#xD;
&#xD;
          -  Regular consumption of natural products containing more than 150 mg of hesperidin or&#xD;
             regular consumption of more than 1 glass of orange juice per day;&#xD;
&#xD;
          -  Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin,&#xD;
             microcrystalline cellulose, magnesium stearate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jocelyn Dupuis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <results_first_submitted>February 22, 2022</results_first_submitted>
  <results_first_submitted_qc>April 6, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2022</results_first_posted>
  <last_update_submitted>April 6, 2022</last_update_submitted>
  <last_update_submitted_qc>April 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Confusion</mesh_term>
    <mesh_term>Anosmia</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04715932/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04715932/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04715932/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>216 subjects were randomized into the study with 109 assigned to placebo and 107 to hesperidin.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hesperidin 1000mg</title>
          <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
        <group group_id="P2">
          <title>Placebo 1000mg</title>
          <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hesperidin 1000mg</title>
          <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
        <group group_id="B2">
          <title>Placebo 1000mg</title>
          <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.31" spread="13.02"/>
                    <measurement group_id="B2" value="40.67" spread="11.26"/>
                    <measurement group_id="B3" value="40.98" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>KG/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.12" spread="6.38"/>
                    <measurement group_id="B2" value="28.21" spread="6.82"/>
                    <measurement group_id="B3" value="28.16" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Hypertension</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Hypertension</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Respiratory Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Respiratory Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Asthma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Asthma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With COPD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without COPD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary Fibrosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Pulmonary Fibrosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Pulmonary Fibrosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other Respiratory Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Other Respiratory Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Other Respiratory Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With COVID-19 Symptoms at Day 3.</title>
        <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With COVID-19 Symptoms at Day 3.</title>
          <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subject has at least one of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject has none of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3849</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With COVID-19 Symptoms at Day 7.</title>
        <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With COVID-19 Symptoms at Day 7.</title>
          <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subject has at least one of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject has none of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3139</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With COVID-19 Symptoms at Day 10.</title>
        <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With COVID-19 Symptoms at Day 10.</title>
          <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subject has at least one of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject has none of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5886</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With COVID-19 Symptoms at Day 14.</title>
        <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With COVID-19 Symptoms at Day 14.</title>
          <description>Number of subjects with any of the following COVID-19 symptoms: fever (temperature &gt; 38 degrees), cough, shortness of breath or anosmia, at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subject has at least one of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject has none of the selected COVID-19 symptoms.</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2328</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of COVID-19 Symptoms at Day 3.</title>
        <description>Mean number of COVID-19 symptoms (range 0-13) at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of COVID-19 Symptoms at Day 3.</title>
          <description>Mean number of COVID-19 symptoms (range 0-13) at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="2.52"/>
                    <measurement group_id="O2" value="4.16" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1560</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated poisson regression).</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of COVID-19 Symptoms at Day 7.</title>
        <description>Mean number of COVID-19 symptoms (range 0-13) at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of COVID-19 Symptoms at Day 7.</title>
          <description>Mean number of COVID-19 symptoms (range 0-13) at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.49"/>
                    <measurement group_id="O2" value="2.96" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6233</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated poisson regression)</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of COVID-19 Symptoms at Day 10.</title>
        <description>Mean number of COVID-19 symptoms (range 0-13) at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of COVID-19 Symptoms at Day 10.</title>
          <description>Mean number of COVID-19 symptoms (range 0-13) at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="2.19"/>
                    <measurement group_id="O2" value="1.95" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8290</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated poisson regression)</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of COVID-19 Symptoms at Day 14.</title>
        <description>Mean number of COVID-19 symptoms (range 0-13) at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of COVID-19 Symptoms at Day 14.</title>
          <description>Mean number of COVID-19 symptoms (range 0-13) at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.76"/>
                    <measurement group_id="O2" value="1.40" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9222</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated poisson regression)</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Complete Disappearance of Any Symptom.</title>
        <description>The descriptive statistics are the number of participants having complete disappearance of any symptom.</description>
        <time_frame>From randomization to occurence of first event, assessed up to 14 days</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complete Disappearance of Any Symptom.</title>
          <description>The descriptive statistics are the number of participants having complete disappearance of any symptom.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete disappearance of COVID-19 symptoms after randomization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No complete disappearance of COVID-19 symptoms after randomization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8834</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Cough Symptom.</title>
        <description>Number of subjects with the cough symptom at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Cough Symptom.</title>
          <description>Number of subjects with the cough symptom at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9416</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Cough Symptom.</title>
        <description>Number of subjects with the cough symptom at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Cough Symptom.</title>
          <description>Number of subjects with the cough symptom at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6296</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Cough Symptom.</title>
        <description>Number of subjects with the cough symptom at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Cough Symptom.</title>
          <description>Number of subjects with the cough symptom at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3711</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Cough Symptom.</title>
        <description>Number of subjects with the cough symptom at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Cough Symptom.</title>
          <description>Number of subjects with the cough symptom at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without Cough Symptom</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5696</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Fever.</title>
        <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Fever.</title>
          <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7583</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Fever.</title>
        <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Fever.</title>
          <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8091</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>3.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Fever.</title>
        <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Fever.</title>
          <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the Presence of Fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the Presence of Fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5591</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>9.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Fever.</title>
        <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Fever.</title>
          <description>Number of subjects with the presence of fever (temperature &gt; 38 degrees) at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of fever</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9983</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Shortness of Breath.</title>
        <description>Number of subjects with the presence of shortness of breath at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Shortness of Breath.</title>
          <description>Number of subjects with the presence of shortness of breath at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1068</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Shortness of Breath.</title>
        <description>Number of subjects with the presence of shortness of breath at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Shortness of Breath.</title>
          <description>Number of subjects with the presence of shortness of breath at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8382</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Shortness of Breath.</title>
        <description>Number of subjects with the presence of shortness of breath at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Shortness of Breath.</title>
          <description>Number of subjects with the presence of shortness of breath at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5912</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Shortness of Breath.</title>
        <description>Number of subjects with the presence of shortness of breath at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Shortness of Breath.</title>
          <description>Number of subjects with the presence of shortness of breath at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of shortness of breath</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Anosmia.</title>
        <description>Number of subjects with the presence of anosmia at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Anosmia.</title>
          <description>Number of subjects with the presence of anosmia at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3686</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Anosmia.</title>
        <description>Number of subjects with the presence of anosmia at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Anosmia.</title>
          <description>Number of subjects with the presence of anosmia at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8711</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Anosmia.</title>
        <description>Number of subjects with the presence of anosmia at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Anosmia.</title>
          <description>Number of subjects with the presence of anosmia at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9124</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Anosmia.</title>
        <description>Number of subjects with the presence of anosmia at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Anosmia.</title>
          <description>Number of subjects with the presence of anosmia at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of anosmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2952</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Feverish or Chills.</title>
        <description>Number of subjects with the presence of feverish or chills at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Feverish or Chills.</title>
          <description>Number of subjects with the presence of feverish or chills at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5894</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Feverish or Chills.</title>
        <description>Number of subjects with the presence of feverish or chills at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Feverish or Chills.</title>
          <description>Number of subjects with the presence of feverish or chills at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7887</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Feverish or Chills.</title>
        <description>Number of subjects with the presence of feverish or chills at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Feverish or Chills.</title>
          <description>Number of subjects with the presence of feverish or chills at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6348</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>2.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Feverish or Chills.</title>
        <description>Number of subjects with the presence of feverish or chills at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Feverish or Chills.</title>
          <description>Number of subjects with the presence of feverish or chills at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of feverish or chills</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4257</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>3.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Sore Throat.</title>
        <description>Number of subjects with the presence of sore throat at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Sore Throat.</title>
          <description>Number of subjects with the presence of sore throat at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1113</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Sore Throat.</title>
        <description>Number of subjects with the presence of sore throat at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Sore Throat.</title>
          <description>Number of subjects with the presence of sore throat at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2613</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Sore Throat.</title>
        <description>Number of subjects with the presence of sore throat at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Sore Throat.</title>
          <description>Number of subjects with the presence of sore throat at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7273</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Sore Throat.</title>
        <description>Number of subjects with the presence of sore throat at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Sore Throat.</title>
          <description>Number of subjects with the presence of sore throat at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of sore throat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8909</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Runny Nose.</title>
        <description>Number of subjects with the presence of runny nose at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Runny Nose.</title>
          <description>Number of subjects with the presence of runny nose at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1438</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Runny Nose.</title>
        <description>Number of subjects with the presence of runny nose at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Runny Nose.</title>
          <description>Number of subjects with the presence of runny nose at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3440</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Runny Nose.</title>
        <description>Number of subjects with the presence of runny nose at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Runny Nose.</title>
          <description>Number of subjects with the presence of runny nose at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5968</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Runny Nose.</title>
        <description>Number of subjects with the presence of runny nose at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Runny Nose.</title>
          <description>Number of subjects with the presence of runny nose at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of runny nose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3620</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>3.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
        <description>Number of subjects with the presence of nausea/vomiting at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
          <description>Number of subjects with the presence of nausea/vomiting at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0875</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>4.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
        <description>Number of subjects with the presence of nausea/vomiting at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
          <description>Number of subjects with the presence of nausea/vomiting at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8397</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
        <description>Number of subjects with the presence of nausea/vomiting at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
          <description>Number of subjects with the presence of nausea/vomiting at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6265</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>4.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
        <description>Number of subjects with the presence of nausea/vomiting at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Nausea/Vomiting.</title>
          <description>Number of subjects with the presence of nausea/vomiting at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8528</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>8.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Headache.</title>
        <description>Number of subjects with the presence of headache at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Headache.</title>
          <description>Number of subjects with the presence of headache at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2983</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Headache.</title>
        <description>Number of subjects with the presence of headache at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Headache.</title>
          <description>Number of subjects with the presence of headache at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5611</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Headache.</title>
        <description>Number of subjects with the presence of headache at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Headache.</title>
          <description>Number of subjects with the presence of headache at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4643</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Headache.</title>
        <description>Number of subjects with the presence of headache at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Headache.</title>
          <description>Number of subjects with the presence of headache at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5063</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of General Weakness.</title>
        <description>Number of subjects with the presence of general weakness at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of General Weakness.</title>
          <description>Number of subjects with the presence of general weakness at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2292</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of General Weakness.</title>
        <description>Number of subjects with the presence of general weakness at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of General Weakness.</title>
          <description>Number of subjects with the presence of general weakness at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6097</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of General Weakness.</title>
        <description>Number of subjects with the presence of general weakness at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of General Weakness.</title>
          <description>Number of subjects with the presence of general weakness at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8389</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of General Weakness.</title>
        <description>Number of subjects with the presence of general weakness at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of General Weakness.</title>
          <description>Number of subjects with the presence of general weakness at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of general weakness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9764</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Pain.</title>
        <description>Number of subjects with the presence of pain at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Pain.</title>
          <description>Number of subjects with the presence of pain at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4403</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Pain.</title>
        <description>Number of subjects with the presence of pain at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Pain.</title>
          <description>Number of subjects with the presence of pain at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5112</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Pain.</title>
        <description>Number of subjects with the presence of pain at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Pain.</title>
          <description>Number of subjects with the presence of pain at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9306</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Pain.</title>
        <description>Number of subjects with the presence of pain at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Pain.</title>
          <description>Number of subjects with the presence of pain at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6046</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
        <description>Number of subjects with the presence of irritability/confusion at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
          <description>Number of subjects with the presence of irritability/confusion at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6963</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
        <description>Number of subjects with the presence of irritability/confusion at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
          <description>Number of subjects with the presence of irritability/confusion at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4250</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
        <description>Number of subjects with the presence of irritability/confusion at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
          <description>Number of subjects with the presence of irritability/confusion at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8797</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>4.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
        <description>Number of subjects with the presence of irritability/confusion at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Irritability/Confusion.</title>
          <description>Number of subjects with the presence of irritability/confusion at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of irritability/confusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2634</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>37.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Diarrhea.</title>
        <description>Number of subjects with the presence of diarrhea at day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Diarrhea.</title>
          <description>Number of subjects with the presence of diarrhea at day 3.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2710</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Diarrhea.</title>
        <description>Number of subjects with the presence of diarrhea at day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Diarrhea.</title>
          <description>Number of subjects with the presence of diarrhea at day 7.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1748</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>4.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Diarrhea.</title>
        <description>Number of subjects with the presence of diarrhea at day 10.</description>
        <time_frame>Day 10</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Diarrhea.</title>
          <description>Number of subjects with the presence of diarrhea at day 10.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8513</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With the Presence of Diarrhea.</title>
        <description>Number of subjects with the presence of diarrhea at day 14.</description>
        <time_frame>Day 14</time_frame>
        <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Hesperidin 1000mg</title>
            <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 1000mg</title>
            <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With the Presence of Diarrhea.</title>
          <description>Number of subjects with the presence of diarrhea at day 14.</description>
          <population>Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without the presence of diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7906</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed model (repeated binary logistic regression)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected between randomization/baseline until the end of study visit (up to 14 days).</time_frame>
      <desc>Subjects reporting multiple TEAEs within a given system organ class/preferred term were counted only once within the category.&#xD;
Results are based on safety population. Table of adverse events includes serious adverse events. Number of Participants at Risk differs from the number of participants assigned to the arm or comparison group. One participant from the placebo group is not part of the safety population. However, &quot;All-Cause Mortality&quot; is on the intention to treat population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hesperidin 1000mg</title>
          <description>Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
        <group group_id="E2">
          <title>Placebo 1000mg</title>
          <description>Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only one dosage regimen of hesperidin was tested in this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Jocelyn Dupuis (Principal Investigator)</name_or_title>
      <organization>Montreal Heart Institute</organization>
      <phone>514 376-3330 ext 3477</phone>
      <email>jocelyn.dupuis@icm-mhi.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

